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Abstract
Kisspeptins, the ligands of the kisspeptin receptor known for its roles in reproduction and cancer, are also vasoconstrictor
peptides in atherosclerosis-prone human aorta and coronary artery. The aim of this study was to further investigate the
cardiovascular localisation and function of the kisspeptins and their receptor in human compared to rat and mouse heart.
Immunohistochemistry and radioligand binding techniques were employed to investigate kisspeptin receptor localisation,
density and pharmacological characteristics in cardiac tissues from all three species. Radioimmunoassay was used to detect
kisspeptin peptide levels in human normal heart and to identify any pathological changes in myocardium from patients
transplanted for cardiomyopathy or ischaemic heart disease. The cardiac function of kisspeptin receptor was studied in
isolated human, rat and mouse paced atria, with a role for the receptor confirmed using mice with targeted disruption of
Kiss1r. The data demonstrated that kisspeptin receptor-like immunoreactivity localised to endothelial and smooth muscle
cells of intramyocardial blood vessels and to myocytes in human and rodent tissue. [125I]KP-14 bound saturably, with
subnanomolar affinity to human and rodent myocardium (KD = 0.12 nM, human; KD = 0.44 nM, rat). Positive inotropic effects
of kisspeptin were observed in rat, human and mouse. No response was observed in mice with targeted disruption of Kiss1r.
In human heart a decrease in cardiac kisspeptin level was detected in ischaemic heart disease. Kisspeptin and its receptor
are expressed in the human, rat and mouse heart and kisspeptins possess potent positive inotropic activity. The
cardiovascular actions of the kisspeptins may contribute to the role of these peptides in pregnancy but the consequences of
receptor activation must be considered if kisspeptin receptor agonists are developed for use in the treatment of
reproductive disorders or cancer.
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Introduction
The pairing of the kisspeptin receptor (originally named
GPR54, [1]) encoded by the KISS1R gene, with its cognate ligand,
kisspeptin, in 2001 [2–4] led to a number of discoveries regarding
the physiological functions of this system. Originally named
metastin for its ability to inhibit the metastasis of some cancers
[5,6], kisspeptin has also been shown to be involved in trophoblast
invasion during placentation [7]. However, recent interest has
focused on kisspeptin as a crucial activator of the hypothalamic-
pituitary-gonadal axis [8,9]. Investigations in rats, mice, monkeys,
sheep and humans have revealed that kisspeptin/kisspeptin
receptor integrate internal and environmental cues to regulate
the hypothalamic-pituitary-gonadal axis [10–21].
Kisspeptin, or KP-54, is a member of a larger group of peptides,
the RF amides, named after their shared C-terminal amino acids
[22]. RF amides have wide ranging roles in reproduction, feeding,
blood pressure regulation and pain modulation with kisspeptins
most closely implicated in reproduction and energy balance
[21,23–27]. KP-54 is cleaved from a single precursor, encoded by
the KISS1 gene, and smaller fragments of kisspeptin have been
identified that are cleaved from KP-54 by unidentified proteases.
These fragments, KP-14, KP-13 and KP-10, retain biological
activity [3], suggesting that some or all of the C-terminal ten
amino acids are essential for receptor activation. Cleavage of the
three C-terminal amino acids of kisspeptin by the gelatinases
MMP-2 and MMP-9 produces inactive fragments [28]. Addition-
ally, kisspeptins are able to down-regulate MMPs, at both the
transcriptional [29] and protein [30] levels. This may represent
different levels/points of regulatory feedback under various
circumstances, for instance in the different stages of pregnancy
or in pathological states.
We have recently identified a further role for kisspeptin as a
vasoactive peptide [31]. We detected kisspeptin and kisspeptin
receptor expression in human vasculature, and intriguingly found
this to be restricted to the aorta, coronary artery and umbilical
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vein, vessels with the same developmental origin. We also showed
kisspeptin to be a potent vasoconstrictor in human coronary artery
and umbilical vein [31], presumably via activation of the smooth
muscle receptors. However, to our knowledge, a cardiac role of
kisspeptin has not yet been investigated in man, nor any
cardiovascular effects identified in other species. Our aim was
therefore to compare the expression and pharmacological
characteristics of the kisspeptin receptor in human, rat and mouse
cardiac tissues. In human heart we have now demonstrated
expression of mRNA encoding the kisspeptin receptor in
cardiomyocytes and receptor protein was detected in human
atrial and ventricular myocardium. Functionally, kisspeptins
elicited potent inotropic activity in human paced atrial strips.
Comparable receptor localisation and function were demonstrated
in rat and mouse heart, and importantly loss of inotropic function
of kisspeptins was observed in mice in which the Kiss1r gene is
disrupted (Kiss1r2/2), confirming a direct role for the kisspeptin
receptor. A potential alteration in cardiac kisspeptin receptor
signaling was indicated by a significant decrease in kisspeptin levels
in the hearts of patients with ischaemic heart disease, and a trend
to a corresponding compensatory increase in receptor density.
Results
Expression of mRNA encoding kisspeptin receptor in
human cardiomyocytes
Integrity of the cDNA samples was established by the
identification of bands of the expected size for products of the b-
actin gene (353 bp) (Figure 1 A and 1B). The specificity of the
kisspeptin receptor mRNA primers was confirmed by the presence
of bands of the expected size (198 bp) in samples from human
myometrium (Figure 1A), a tissue previously reported to express
kisspeptin receptor protein [3]. Expression of kisspeptin receptor
mRNA was identified in samples of human isolated cardiomyo-
cytes (Figure 1B) confirming the potential of human heart tissue to
express kisspeptin receptor protein.
Immunohistochemical localisation of kisspeptin and
kisspeptin receptor protein
Western blotting revealed bands of the appropriate size for the
kisspeptin receptor; rat 43 kDa (Figure 2A); mouse 75 kDa
(Figure 2B); human 42 kDa (Figure 2C), that were consistent with
previous reports [32]. In tissue from all three species, bands were
attenuated by pre-absorption of the primary antibody with the
appropriate immunizing peptide.
In sections of human heart kisspeptin receptor-like immunore-
activity (2LI) was detected in myocardium from all regions of
explanted hearts investigated (right and left atria, right and left
ventricle and interventricular septum) and in sections of atrial
appendage obtained from coronary artery bypass graft operations.
Within the myocardium, receptor protein localised to both
cardiomyocytes (Figure 3 A–C) and intramyocardial blood vessels,
with cell specific markers identifying localisation to both vascular
smooth muscle (Figure 3 D–F) and endothelial cells (Figure 3 G–I).
Kisspeptin-like immunoreactivity was detected in vascular
(Figure 3 J–L) and endocardial endothelial cells in addition to
cardiomyocytes (Figure 3 M–O).
Similar expression patterns were obtained in rat cardiovascular
tissues. Kisspeptin receptor-LI was present in endothelial cells and
to a lesser extent to the underlying smooth muscle of small
diameter intramyocardial blood vessels (Figure 4A) and large
diameter thoracic aorta (Figure 4B) and to endocardial endothelial
cells lining the chambers of the heart and surrounding myocytes
(Figure 4D). Specificity of staining was confirmed by comparison
to pre-immune controls (for example Figure 4C and E). Using
confocal microscopy kisspeptin receptor-LI (green fluorescence)
was identified in rat cardiomyocytes (Figure 4F) and co-localised
with markers for both vascular smooth muscle cells (Figure 4 G–I)
and endothelial cells (Figure 4 J–L). Kisspeptin-LI exhibited a
more discrete localisation to endocardial and vascular endothelial
cells with low expression in surrounding cardiomyocytes (Figure 4
M–O).
In mouse heart kisspeptin receptor-LI localised to cardiomyo-
cytes and intramyocardial blood vessels (Figure 5A), confirmed by
dual labeling fluorescent microscopy (Figure 5C–E). Kisspeptin
receptor–LI was not observed in Kiss1r2/2 mice (Figure 5F–G).
Similarly, kisspeptin-LI was present in small blood vessels and
cardiomyocytes (Figure 5B) and co-localised with von Willebrand
factor to endothelial cells lining the small blood vessels and
chambers of the mouse heart (Figure 5 I–K) but was absent in
sections of heart from Kiss12/2 mice (Figure 5L–N).
[125I]KP-14 binding in human and rat heart
By receptor autoradiography specific binding of [125I]KP-14
was observed in all regions of human and rat myocardium.
Additionally, specific binding was detected in the smooth muscle of
human aorta, human small coronary resistance vessels and rat
aorta. Receptor densities were similar for human myocardium
from all regions (P,0.05, ANOVA), although higher levels were
observed in aorta (Table 1).
Figure 1. Detection of mRNA for kisspeptin receptor in human cardiomyocytes. (A) Expression of kisspeptin receptor mRNA in samples
(n = 3) of human myometrium (Lanes 1–3), used as a control to confirm the specificity of PCR primers as this is a tissue in which the receptor protein
has been previously identified. The integrity of the samples was confirmed by detection of the b-actin product of the expected size, 353 bp,
indicating integrity of cDNA and absence of gDNA. PCR product size was determined using a 100 bp DNA ladder (Lane 4) (B) Expression of kisspeptin
receptor mRNA (expected size 198 bp) in cDNA from human isolated cardiomyocyte samples (n = 3, lanes 3–5). b-Actin control (Lane 2) acted as a
positive control and the absence of cDNA (Lane 1) served as a negative control with a 100 bp DNA ladder (Lane 6).
doi:10.1371/journal.pone.0027601.g001
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In saturation experiments [125I]KP-14 bound monophasically in
human right atria. Binding was saturable with subnanomolar
affinity (KD 0.1260.05 nM, BMAX 865 fmol mg
21 protein,
n = 3). In rat heart [125I]KP-14 also bound with a comparable
subnanomolar affinity and receptor density (KD 0.4460.14 nM,
BMAX 1162 fmol mg
21, n = 6). In both species Hill slopes were
close to unity suggesting presence of only one binding site, or
multiple sites with the same affinity.
Inotropic activity in atrial tissue
In human paced atrial strips and rat paced paired atria there
was no significant difference in the mean baseline contractile force
generated at 50% of optimum resting tension or in mean
contractile force in response to 8.95 mM CaCl2 between tissues
used to test KP-10 and KP-54. In human atria both peptides were
positive inotropes with comparable sun-nanomolar potency (KP-
10 pD2 9.9960.73, n = 5; KP-54 pD2 10.3960.44, n= 5) and
maximum responses (KP-10 EMAX 59610%, KP-54 EMAX
82613%) (Figure 6 A, B).
Inotropic responses in rat paired atria were of similar potency
but with lower maximum response than for human atria (KP-10
pD2 9.7060.44, EMAX 3165%, n= 7; KP-54 pD2 9.8560.63,
EMAX 1462%, n= 4) (Figure 6 A, B). Lusitropic effects were not
observed in either species to either peptide (Figure 6C).
In mouse atria, positive inotropic effects of KP-54 were
observed, with comparable potency (pD2 10.2160.34, n = 6) to
those in human and rat and maximum response (Emax 2664%)
similar to that obtained in rat atria. No response to kisspeptin was
detected in mice with targeted disruption of Kiss1r (Figure 6D).
Vasoconstrictor activity in endothelium-denuded rat
aorta
Aortic rings from all rats tested contracted to ET-1 (pD2
8.1360.11, EMAX 9961%, n= 7). Responses were more variable
for the kisspeptins, with vasoconstrictor responses obtained to KP-
10 (pD2 9.9660.53, EMAX 76617% KCl) in tissues from 4
animals and KP-54 in tissues from 3 animals (pD2 10.4760.26,
EMAX 9761% KCl) (Figure 6 E).
KISS1 in human heart disease
The level of kisspeptin-LI detected in myocardium of right atria
from control hearts (n = 4) was not different from that in
myocardium from patients transplanted for dilated cardiomyop-
athy but there was a significant reduction in myocardium from
right atria of patients transplanted for ischaemic heart disease
(P,0.05, ANOVA). In left ventricle, there was no significant
difference in kisspeptin-LI between the three groups (P.0.05)
(Figure 7).
To determine if the change in peptide level detected in the right
atria was associated with an alteration in receptor density,
saturation analysis was performed with [125I]KP-14. No significant
difference in receptor density or binding affinity in right atria from
control, dilated cardiomyopathy (DCM) or ischaemic heart disease
(IHD) patients was observed (Table 2).
Discussion
The RF-amide peptide family, which also includes prolactin
releasing peptide, are known to have roles in cardiovascular
regulation, both centrally [33] and peripherally [34,35]. However,
to date mRNA studies of kisspeptin receptor distribution in whole
heart samples have reported low but varying mRNA expression by
northern blot [2], expression was not detected by PCR [3,4,32]
except by Sawyer and colleagues, who were also able to detect
mRNA encoding murine kisspeptin, albeit at very low copy
number [46]. We now report for the first time, the expression of
kisspeptin and the kisspeptin receptor protein in human, rat and
mouse heart, and have shown that kisspeptins are potent positive
inotropes in in vitro cardiac preparations from these species.
Phylogenetic analysis has revealed that the kisspeptin receptor is
most closely related to the galanin receptors (GAL1–3). Galanin
receptors are not thought to mediate major cardiovascular actions,
however, there is evidence that galanin can modulate cholinergic
transmission, inhibiting parasympathetic slowing of the heart
following activation of the cardiac sympathetic system [36] for
example after myocardial infarction [37]. The urotensin II
receptor (UT) shows some sequence similarity to both kisspeptin
and galanin receptors and urotensin-II has been shown to be a
vasoactive peptide [38] and a potent inotrope in human heart
[39].
Consistent with the inotropic actions of the kisspeptins we have
shown that kisspeptin receptor localises to cardiomyocytes in
sections of human, rat and mouse heart. Furthermore, we have
confirmed receptor protein expression in human and rat heart by
receptor autoradiography with saturation binding analysis reveal-
Figure 2. Detection of kisspeptin receptor protein in rat, mouse
and human heart. Western blot analysis of rabbit anti-kisspeptin
receptor (230–244, rat/mouse) serum on membrane preparations of (A)
rat (n = 3) and (B) mouse (n = 3) heart revealed a single band of the
expected size, 43 kDa or 75 kDa respectively (lanes 1–3). Pre-absorption
of the primary antibody with the immunizing peptide resulted in
attenuation of the bands (lanes 4–6). (C) Human left ventricle (n = 4) was
probed with rabbit anti-kisspeptin receptor (375–398, human) (lanes 1–
4) producing a band at 42 kDa, the expected size, which was
attenuated when the primary antibody was pre-absorbed with the
immunizing peptide (lanes 5–8). Protein marker positions are shown
alongside the blots.
doi:10.1371/journal.pone.0027601.g002
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ing comparable subnanomolar affinity in both species for the
radioligand [125I]KP-14, comparable to that previously reported
in human blood vessel smooth muscle [31] and cell lines
expressing the receptor [3,4]. The receptor densities that we
measured were similar to other inotropic peptides in native human
tissue such as apelin (BMAX 3.1 fmol mg
21, [40]). We found no
evidence for more than one receptor subtype, as predicted from
the genome, in contrast to non-mammalian species where two
subtypes of kisspeptin receptor have been cloned, Kiss1r and Kiss2r
[41].
The creation of mice with targeted disruption of the Kiss1r gene
[18] has permitted further investigations into the inotropic effects
of kisspeptins. In atria from wild-type mice, KP-54 was a potent
positive inotropic agent, with a similar potency to that obtained in
rat and human tissues and a similar maximum response to that
observed in rat. The differences in the EMAX values for both KP-
10 and KP-54 that we observed between human and rodent may
reflect altered responsiveness of the rodent receptor to the human
peptides used in these experiments. KP-10 differs by one amino
acid: the C-terminal residue is phenylalanine in human and
Figure 3. Cellular localisation of kisspeptin receptor-LI in human cardiovascular tissues. Representative photomicrographs showing
kisspeptin receptor-LI localised to cardiomyocytes (A–C), co-localised with smooth muscle a-actin (red fluorescence E) to vascular smooth muscle of
intramyocardial blood vessels (F) and with von-Willebrand factor (red fluorescence B, H) to vascular endothelial cells (A, I). Kisspeptin-LI (green
fluorescence J, M) co-localised with vonWillebrand factor (K, N) to vascular (L) and endocardial (O) endothelial cells and surrounding cardiomyocytes (O).
doi:10.1371/journal.pone.0027601.g003
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tyrosine in rat and mouse. The full-length kisspeptin sequence,
KP-54, contains 22 amino acid differences. Significantly, no
inotropic response to KP-54 was detected in the Kiss1r2/2 mice,
confirming that the inotropic effects of kisspeptin are mediated
solely by this receptor, at least in this species.
Circulating levels of kisspeptin are low, (0.8360.19 pM, [31])
and so we were interested to identify a local cardiac source of
kisspeptin. In all three species we detected kisspeptin-LI both to
cardiomyocytes and to endocardial endothelial cells lining the
chambers of the heart. Whether this endogenous cardiac
kisspeptin system has a significant physiological role remains to
be determined, however we have some evidence that levels of
kisspeptin are altered in ischaemic heart disease with a significant
reduction of peptide expression in right atria. This may not be
Figure 4. Localisation of kisspeptin receptor-LI in rat cardiovascular tissues. Representative photomicrographs showing peroxidase-
antiperoxidase detection of kisspeptin receptor–LI to endothelial cells and underlying smooth muscle of (A) a small intramyocardial blood vessel, (B)
large diameter thoracic aorta and (D) endothelial cells lining chambers of the heart. Pre-absorbed controls (C) and (F) obtained in adjacent tissue
sections. Cellular localisation of kisspeptin receptor-LI was also identified as green fluorescence in (F) rat cardiomyocytes, (G) smooth muscle cells and
(J) endothelial cells. Cell specific markers (H) smooth muscle a-actin and (K) von Willebrand factor are shown as red fluorescence and co-localisation
with kisspeptin receptor confirmed by yellow fluorescence in the overlays (I, L). Kisspeptin-LI (M) localised to endothelial cells (O) identified by von
Willebrand factor (N,) and to surrounding cardiomyocytes (M,O).
doi:10.1371/journal.pone.0027601.g004
Inotropic Action of Kisspeptin
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unexpected; in the failing heart, both MMP-2 and MMP-9 are up-
regulated [42] and, importantly, these enzymes cleave kisspeptins to
biologically inactive products [28] that would not be detected by our
radioimmunoassay. Changes in endogenous ligand concentration
for GPCRs can result in changes in expression levels of receptor
protein and we did detect a trend to increased receptor density in
the right atria of diseased hearts which was not significant, but may
be a consequence of downregulation of peptide.
Our discovery that kisspeptins are positive inotropic agents in
human and rodent heart is the first report of such activity. These
inotropic effects were very potent and comparable to other
peptides such as endothelin (pD2= 8.9) [43] and apelin (pD2= 9.9)
[44]. A number of existing studies have shown that the kisspeptin
receptor is coupled to Gq/11, leading to phospholipase C activation
and Ca2+ release [3,4,32] and that Rho and Rho-associated kinase
are activated by KP-10 [45]. Activation of these signaling
Figure 5. Localisation of kisspeptin receptor-LI in mouse heart. Representative photomicrographs showing peroxidase anti-peroxidase
staining for (A) kisspeptin receptor-LI and (B) kisspeptin-LI in vascular and endocardial endothelial cells in mouse heart. In wild type mice kisspeptin
receptor-LI (green fluorescence, C) and von-Willebrand factor-LI (red fluorescence D) co-localised (E) to vascular endothelial cells with receptor-LI also
localised to adjacent cardiomyocytes whereas (F) no receptor-LI was detected in heart from Kiss1r2/2 mice although endothelial cells could be
visualized (G, H). Similarly, kisspeptin co-localised with von Willebrand factor in vascular endothelial cells (I–K) but was absent in heart tissue from
Kiss12/2 mice (L–M). Scale bars are 50 mm.
doi:10.1371/journal.pone.0027601.g005
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pathways would be consistent with function as both an inotropic
agent and a vasoconstrictor. We have previously shown that in the
human vasculature expression of kisspeptin receptor in large
diameter human vessels was restricted to vessels with a common
developmental origin, umbilical vein, coronary artery and aorta,
the latter prone to development of atherosclerosis [31]. In the
present study we have confirmed that kisspeptin receptor protein is
expressed on both the vascular smooth muscle and endothelial
cells of small intramyocardial vessels in the hearts of all three
species in addition to these cell types in the rat aorta. Functional
experiments confirmed that activation of the smooth muscle
receptor in rat aorta mediated vasoconstriction. Although
responses were variable, in those tissues that did contract the
kisspeptins were more potent than ET-1. In a recent study Sawyer
and colleagues [46] have demonstrated that injected KP-10
attenuated microvascular cutaneous blood flow in mice, suggesting
that kisspeptins may have a more generalized constrictor potential
on resistance blood vessels compared to larger vessels. Consistent
with kisspeptins acting as paracrine mediators we localized
kisspeptin-LI to vascular endothelial cells lining the small
intramyocardial vessels in human, rat and mouse heart. KP-54
was originally identified as a metastasis suppressor protein [5] and
subsequently shown to be anti-angiogenic [47]. Locally mediated
vasoconstriction may be one mechanism by which kisspeptins
modify blood flow to tumors and limit their metastatic potential.
Humans with mutations in KISS1R develop hypogonadotropic
hypogonadism, characterised by decreased levels of sex steroids
and delayed puberty [9]. However, no cardiovascular phenotype
has been observed in these patients. The same is also true in mice
with targeted disruption of either Kiss1r or Kiss1, suggesting that
the kisspeptin system is not crucial for normal cardiovascular
physiology. In healthy individuals, circulating kisspeptin levels are
very low, perhaps reflecting, as suggested for the heart, local rather
than endocrine actions. However, plasma kisspeptin concentra-
tions are markedly increased 10000-fold above normal levels in
pregnancy [48], and we can speculate that under these conditions
kisspeptin may contribute to the adaptive increase in cardiac
output [49]. There is also evidence that kisspeptins contribute to
the pathogenesis of pre-eclampsia. Kiss1 mRNA has been
reported to be increased in pre-eclampsia patients [50] and if
kisspeptins have a general vasoconstrictor action in the microvas-
culature then this increase may contribute to the hypertensive
Table 1. Autoradiographical analysis of [125I]KP-14 binding
densities in human and rat cardiovascular tissues.
Tissue
[125I]KP-14 specific
binding (amol mm22) n
Human Left atria 59616 3
Right atria 3667 3
Left ventricle 3468 3
Right ventricle 3167 3
Interventricular septum 29610 3
Apex 2766 4
Atrial appendage 51615 4
Small resistance vessel 463 5
Aorta 214646 6
Rat Heart 29610 5
Aorta 2162 3
Data are expressed as mean 6 SEM. n-Values are the number of individuals/
animals from which tissue was obtained.
doi:10.1371/journal.pone.0027601.t001
Figure 6. Functional responses to kisspeptins in human, rat and mouse cardiovascular tissues. Concentration-response curves showing
positive inotropic effects of (A) KP-10 and (B) KP-54 on strips of human atrial appendage (N) and rat atria (&). An example of the chart recorder trace
for a single human atrial strip is shown (C). The chart recorder speed was increased before the addition of each concentration of kisspeptin to allow
analysis of lusitropic responses (half time to peak force and half time to relaxation) for individual peaks. (D) Concentration-response curves showing
the positive inotropic effect of KP-54 on Kiss1r+/+ mouse atria (N) and lack of effect on Kiss1r2/2 atria (&). (E) Vasoconstrictor responses to KP-10 (N),
KP-54 (&) and ET-1 (m) in endothelium-denuded rat aortic rings. All values are mean 6SEM.
doi:10.1371/journal.pone.0027601.g006
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phenotype in these individuals. However, a conflicting report
detected decreased Kiss1 mRNA levels [51] in pre-eclampsia,
suggesting this is an area that warrants further investigation.
In conclusion, we have detected the expression of kisspeptin and
kisspeptin receptor in human, rat and mouse myocardium and
vasculature and have shown kisspeptins to be potent positive
inotropes in the atria of these three species. The (patho)physio-
logical relevance of these data remains to be determined.
However, small molecular weight kisspeptin receptor agonists
may have promise as novel therapies for attenuation of metastasis
in tumors or for triggering puberty in individuals with delayed
onset. Therefore, it is important to recognize at an early stage of
the development of such compounds their potential for cardio-
vascular actions.
Materials and Methods
Ethics Statement
Anonymised human cardiovascular tissue samples were used in
this study with local ethical approval from the Huntingdon
Research Ethics Committee (REC 05/Q0104/142). The samples
were obtained from Papworth Hospital Research Tissue Bank
(Cambridgeshire 1 Research Ethics Committee reference 08/
H0304/56, samples collected with written informed patient
consent). Transgenic mice and wild type litter mates were bred
and maintained in the combined animal facility, Department of
Physiology, Development and Neuroscience, Cambridge Univer-
sity, under Home Office project licence number PPL 80/2143.
This project was subject to approval by a Local Ethical Committee
at the University of Cambridge before submission to the Home
Office. Animals were maintained on a normal diet with free access
to water and food, in a climatically controlled environment and
were killed by CO2 exposure in accordance with Schedule 1 of the
U.K. Animals (Scientific Procedures) Act, 1986.
Tissues
Human cardiovascular tissues were from 40 male and 12 female
patients, age range 17–78 years. Ventricular and atrial myocar-
dium, apex and interventricular septum were from the explanted
hearts of patients transplanted for dilated cardiomyopathy,
ischaemic heart disease or from control hearts. Atrial appendages
were obtained from patients receiving coronary artery bypass
grafts. Rat tissues were obtained from male Sprague-Dawley (340–
450 g) and Wistar (215–280 g) rats (Charles River Laboratories,
Margate, UK). Mouse tissues were obtained from adult C57/Bl6/
J (20–30 g) male mice and 129S6/SvEv wild type and transgenic
(Kiss1r2/2 (Gpr54tm1PTL [9]) and Kiss12/2 (Kiss1tm1PTL [18]) male
mice (2–4 months old).
Myocyte isolation, RNA extraction and Reverse
Transcription
Human cardiomyocytes were isolated as previously described
[52]. mRNA was extracted from myometrium and cardiomyocytes
using a single step guanidinium isothiocyanate method. cDNA
synthesis was carried out using Invitrogen SuperScript III First-
Strand Synthesis System for RT-PCR and oligo-dT primer. To
confirm the integrity of the cDNA samples PCR reactions were
performed using primers spanning an intronic region in the b-
actin gene: 59 primer 59-GCTCGTCGTCGACAACGGCT-39;
39 primer 59CAAACATGATCTGGGTCATCTTCTC.
Conditions were 98uC for 1 minute, followed by 40 cycles of 97uC
for 1 minute, 55uC for 30 seconds, 72uC for 1 minute, and a final
extension at 72uC for 10 minutes. Expected product size was 353 bp.
Figure 7. Detection of kisspeptin-LI in human heart. Levels of kisspeptin-LI detected in human right atria and left ventricle compared from
donor hearts (control), hearts from patients transplanted for dilated cardiomyopathy (DCM) or ischaemic heart disease (IHD). Values are mean6 SEM.
For right atria levels of kisspeptin-LI were significantly decreased compared to the other two groups (P,0.05, ANOVA). Inset graph is an example of a
standards curve.
doi:10.1371/journal.pone.0027601.g007
Table 2. Saturation binding analysis of [125I]KP-14 in sections
of human normal and diseased right atria.
KD (nM)
BMAX (fmol
mg21 protein) nH n
Control 0.1260.05 8.064.8 0.8260.10 3
DCM 0.1160.06 10.263.4 1.0060.02 3
IHD 0.4660.17 13.567.0 0.9460.03 3
KD: the concentration of [
125I]KP-14 which at equilibrium occupies 50% of the
binding sites; BMAX: receptor density; nH: Hill coefficient; DCM: dilated
cardiomyopathy; IHD: ischaemic heart disease. Values are mean 6 SEM.
doi:10.1371/journal.pone.0027601.t002
Inotropic Action of Kisspeptin
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Primers for kisspeptin receptor were designed using Invitrogen
oligoperfect TM designer: 59 primer 59-CTCGCTGGTCATCTA-
CGTCA-39; 39 primer, 59-CCAGTTGTAGTTCGGCAGGT-39.
Optimized PCR conditions were 98uC for 1 minute, followed
by 30 cycles of 97uC for 1 minute, 59uC for 30 seconds, 72uC for
1 minute, and a final extension at 72uC for 10 minutes. Expected
product size 198 bp.
The reaction mixtures consisted of 106 PCR buffer, 0.2 mM
dNTPs, 1.5 mM MgCl2, 0.2 mM of each primer, and 1 U of
PlatinumH Taq DNA polymerase. PCR products were separated
by electrophoresis on a 1% agarose gel with ethidium bromide and
sizes estimated by reference to a 100-bp DNA molecular weight
standard. Specificity of the kisspeptin receptor primers was
confirmed using mRNA extracted from human myometrium a
tissue known to express the receptor [3]. Negative controls in
which cDNA was omitted were included for each PCR reaction.
Protein Detection
To examine the expression of kisspeptin receptor protein in rat,
mouse and human heart homogenates, Western blotting was
performed using species specific anti-kisspeptin receptor antibodies
raised against amino acids 230–244 of the rat/mouse receptor
sequence and 375–398 of the human receptor. Briefly, rat and
mouse hearts and human left ventricular tissue were homogenized
in lysis buffer (mM; Tris, 50; MgCl2, 5; EDTA, 5; EGTA, 1;
protease inhibitor cocktail (mM: 4-(2-aminoethyl)benzenesulpho-
nyl fluoride, 104; bestatin, 4; leupeptin, 2; pepstatin A, 1.5; E-64,
1.4; aprotonin, 0.08), 1:1000; pH 7.5 at 22uC), filtered through
gauze and centrifuged at 30 000 g for 30 minutes at 4uC. Pellets
were re-suspended in 1 ml lysis buffer and re-centrifuged. The
resulting pellet was suspended in 500 ml HEPES/KCl buffer (mM;
HEPES, 50; KCl, 13; protease inhibitor cocktail, 1:1000; pH 8.0,
22uC) and protein concentration determined using the Biorad DC
96-well microtitre plate system. Protein samples were reduced and
denatured by heating at 95uC in Laemelli sample buffer (mM:
10% SDS; Glycerol; Tris,1; 1% bromophenol blue; Dithiothreitol
(DTT), 1) and electrophoresed on a 10% SDS-polyacrylamide gel
with molecular weight markers. Samples were transferred to a
polyvinylidene fluoride membrane using a semi-dry blotting
method and blocked in Tris-buffered saline (TBS) (mM: Tris,
0.41) with 5% non-fat dry milk overnight at 4uC. Membranes were
probed with 1:1000 of the appropriate rabbit anti-kisspeptin
receptor serum in TBS/0.5% Tween-20 (TBS/T) and 1% non-fat
dry milk overnight at 4uC before incubation for 1 h at 22uC with
1:5000 goat anti-rabbit horseradish peroxidase (Amersham, Bucks,
U.K.) in TBS/T with 1% non-fat dry milk. Controls were
performed in which the rabbit anti-kisspeptin receptor sera were
incubated with the immunizing peptides (1 mM) overnight, at 4uC
(pre-absorbed control), before probing the membrane; or the
primary antibody was omitted from the protocol (negative
control). Detection was performed with enhanced chemilumines-
cence (ECL) reagent and exposure to Kodak film.
Immunohistochemistry
Immunohistochemistry (IHC) was carried out using standard
techniques [53]. Cryostat-cut sections (10 mm) of rat, mouse and
human heart were fixed in acetone for 10 minutes at 4uC prior,
blocked (to reduce non-specific staining) in PBS for 2 hours at
22uC with either 5% swine serum (SS) for peroxidase anti-
peroxidase IHC or, for dual-labeling fluorescent IHC, in either
5% goat serum (GS) for human and rat tissues or 5% donkey
serum for mouse tissues. Human right atria, rat heart and mouse
heart sections were incubated with the appropriate species specific
anti-kisspeptin receptor or anti-kisspeptin sera. For dual-labeling
fluorescence IHC sections were also incubated with mouse (human
and rat tissues) or sheep (mouse tissues) anti-von Willebrand Factor
(vWF) or mouse anti-smooth muscle alpha actin (SMaA). Controls
were performed by incubating adjacent sections with either
primary antibody pre-absorbed with the immunizing peptide or
pre-immune sera if available or the primary antibody was omitted.
For peroxidase anti-peroxidase IHC, immunoreactivity was
visualized by incubation with swine anti-rabbit secondary antibody
and reaction with 3,39-diaminobenzidine (DAB) and examined
using a bright-field microscope (Olympus UK LTD, Essex, UK).
Images were captured using a U-TV1-X digital camera (Olympus
UK LTD, Essex, UK) and CellD software. For dual-labeling
fluorescence IHC sections were incubated with the species
appropriate AlexaFluor-488 and AlexaFluor-568 conjugated
secondary antibodies before visualization via laser scanning
confocal microscopy (Leica Microsystems, Bucks, UK).
Fluorescence Dual Labeling Immunocytochemistry (ICC)
Sections (10 mm) of human heart were fixed in acetone and
blocked with 5% non-immunized goat serum (GS) in phosphate
buffered saline (PBS). Sections were co-incubated with 1:100
rabbit anti-GPR54 (375–398, human) serum or rabbit anti-KP-10
(KP(45–54)-NH2, human) and 1:50 mouse anti-vWF monoclonal
antibody. Secondary antibody solution contained 1:200 Alexa-
Fluor 488 conjugated goat anti-rabbit serum and AlexaFluor 568
conjugated goat anti-mouse serum. Visualization was carried out
using laser scanning confocal microscopy [31].
Radioligand binding
For receptor autoradiography, cryostat-cut sections of human
(15 mm) or rat (10 mm) heart were pre-incubated with phosphate
binding buffer (mM: NaH2PO4, 50; NaCl, 100; EDTA, 5; MgCl2,
5; protease inhibitor cocktail, 1; pH 7.4) before incubation for 2 h
with 0.2 nM [125I]KP-14 [31]. Unlabelled KP-14 (10 mM) (human
tissues) or KP-10 (1 mM) (rat tissues) defined non-specific binding
in adjacent sections. Equilibrium was broken by washing in
50 mM Tris-HCl buffer, pH 7.4, 4uC before air-drying and
apposition to radiation-sensitive film (Kodak Biomax MR) and
determination of specific binding by computer-assisted densitom-
etry using the Quantimet 970 system (Leica Microsystems, Bucks,
UK).
For saturation analysis, sections were incubated with increasing
concentrations of [125I]KP-14 (20 pM–500 nM for human tissues,
4 pM–2 nM for rat tissues) with 1 mM unlabelled KP-14 or KP-10
included to define non-specific binding in adjacent sections [54].
[125I]KP-14 binding was detected using a gamma counter to
measure disintegrations per minute (dpm) and total protein
content was calculated using the Biorad 96-well microtiter plate
system.
In vitro pharmacology
Paired rat or mouse atria, or 4 mm strips of human atrial
appendage, were mounted in 10 ml organ baths containing
oxygenated Krebs solution at 37uC as described previously [55].
Tension on the tissue was adjusted to 50% of that at which the
maximum force was generated and then paced at 1 Hz, square-
wave pulse, 5 ms duration, with the voltage just above threshold
(,4.0 V). The isometric tension generated to KP-10 and KP-54
(1 pM–300 nM) was recorded and concentration-response curves
constructed. Experiments were terminated by the addition of
6.7 mM CaCl2 (final bath concentration 8.95 mM) and responses
expressed as a % of this CaCl2 maximum.
Rat thoracic aorta was cleaned of connective tissue and cut into
4 mm rings and the endothelial layer removed by gentle rubbing.
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Tissues were set to a basal tension at which the maximum response
to 100 mM KCl was generated and subsequent responses to
kisspeptins were expressed as % of this KCl response [38]. Aortic
rings were then contracted with 10 mM phenylephrine and 1 mM
ACh was added; a reduction in the phenylephrine response of
,10% was taken as evidence of removal of endothelium.
Cumulative concentration-response curves were constructed to
KP-10, KP-54 (10212 M–361029 M) and as a control endothelin-
1 (ET-1, 10210 M–361027 M). Experiments were terminated by
the addition of 100 mM KCl and agonist responses were
expressed as a % of this KCl maximum.
Radioimmunoassay
Pooled human plasma (n = 4, male) was acidified and used for
characterization of the radioimmunoassay (RIA). Samples of
human left and right atria, left and right ventricle, apex and
interventricular septum were homogenized, boiled for 15 min in
0.5 M acetic acid and spun at 20000 g for 30 min at 4uC. Peptides
were extracted using silica based columns, dried and reconstituted
in radioimmunoassay (RIA) buffer (mM: Na2HPO4, 40;
NaH2PO4, 10; Na Azide, 8 and gelatin, 0.025%; Tween 20,
0.05%, pH 7.4 at 22uC).
RIA was carried out using a previously characterised assay [31],
with inter- and intra-assay variation ,10%, a detection limit of
2.8 fmol/tube, an IC50 of 34 fmol/tube and the linear portion of
the curve ranging from 8–200 fmol/tube. Incubates consisted of
100 ml of standard (0–10 nM KP-14) or extracted sample, 100 ml
rabbit anti-KP-10 (KP(45–54)-NH2, human) (1:30000) and 100 ml
[125I]KP-14 (10000–15000 cpm), diluted in RIA buffer. Free and
bound kisspeptin was separated by addition of activated charcoal
and [125I]KP-14 detected using a gamma counter.
Statistical Analysis
Radioligand binding study data were analyzed using the
iterative, non-linear curve fitting programs EBDA and LIGAND
in the KELL package (Biosoft, Cambridge, UK). Pooled KD,
BMAX and Hill slopes (nH) were expressed as mean6SEM and
normalized to protein concentrations. In vitro pharmacology data
agonist responses were expressed as %CaCl2 response in the paced
atrial tissues and %KCl in the vasoconstrictor studies and data
were fitted to a four parameter logistic equation using an iterative
curve-fitting program (FigSys, Biosoft, Cambridge, UK) to obtain
values for potency (pD2: the negative logarithm to the base 10 of
the EC50) and maximum response (EMAX: %CaCl2 or %KCl,
respectively) expressed as mean6SEM. Where appropriate, values
were compared by one-way analysis of variance (ANOVA). In all
cases P,0.05 was considered statistically significant and n-values
were the number of animals or patients from which data were
obtained.
Drugs and Reagents
KP-54, KP-14 and KP-10 (rat/mouse) peptides were custom
synthesised by Severn Biotech (Kidderminster, UK). KP-10
(human) and ET-1 (human) were from Peptide Institute (Osaka,
Japan). [125I]KP-14 (2000 Ci/mmol) was synthesised by Amer-
sham Biosciences (GE Healthcare, Little Chalfont, UK), prepared
from unlabelled KP-14 by direct iodination with sodium [125]-
iodide using the chloramine-T method. Rabbit anti-KISS1 (raised
against amino acids 375–398 of the human receptor sequence)
serum and rabbit anti-KP-10 (KP(45–54)-NH2, human) serum
were from Phoenix Pharmaceuticals (Belmont, CA, USA). Rabbit
anti-Kiss1 serum, raised again amino acids 230–244 of the rat/
mouse KISS1 sequence, was custom synthesised by Severn
Biotech (Kidderminster, UK) and rabbit anti-KP-10 (rat/mouse)
was kindly provided by Dr. Alain Caraty (Unite´ de Physiologie de
la Reproduction et des Comportements, Institut National de la
Recherche Agronomique/Centre National de la Recherche
Scientifique/Universite´ Tours, Nouzilly, France) [56]. Swine
anti-rabbit secondary antibody, mouse anti-vWF and mouse
anti-SMaA were from from Dako UK (Ely, Cambridgeshire,
UK) and sheep anti-vWF was from Abcam (Cambridge, UK).
AlexaFluor488-conjugated goat anti-rabbit, AlexaFluor568-conju-
gated goat anti-mouse, AlexaFluor488-conjugated donkey anti-
rabbit and AlexaFluor568-conjugated donkey anti-sheep second-
ary antibodies were from Molecular Probes (Leiden, The Nether-
lands). All molecular biology reagents, including primers, were
from Invitrogen (Paisley, UK), all other reagents from Sigma-
Aldrich (Poole, UK).
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